BioSpace News Archive

Ovid Therapeutics Inc., a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by rare epilepsies and brain conditions, announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET.

Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced the completion of an oversubscribed $106.6 million Series C financing.

Incyte Corporation announced that its Board of Directors approved a share repurchase authorization of $2.0 billion.

Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms, announced the closing of an oversubscribed $95 million Series C financing.

Moderna, Inc., announced its participation in the following upcoming investor conferences:

Aurora Spine Corporation, a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced it has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results that ended March 31, 2024.

Reneo Pharmaceuticals, Inc. and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

MiNK Therapeutics, Inc. announced that it has entered into a stock purchase agreement to sell securities in a private placement financing for $5.8 million.

ReCode Therapeutics today announced the appointment of Dean J. Mitchell as chairman of its Board of Directors.

Resolve Therapeutics today announced the publication of its phase 2 long COVID results in Clinical Infectious Diseases.